Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...
Parkinson's disease cases are projected to double globally by 2050, reaching 25 million individuals, according to a recent ...
April is Parkinson's Disease Awareness Month, and the American Parkinson Disease Association (APDA) will commemorate the month with ...
Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...
Bhubaneswar: In a groundbreaking achievement, the Institute of Medical Sciences and SUM Hospital has succesfully conducted ...
The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...
JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...
Philip Lewis Pittman Philip Pittman was born on 3/24/1937 in Centerville, Iowa. He passed away in Albuquerque, New Mexico on 2/23/2025 due to advanced symptoms of Parkinson's Disease. Phil spent most ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback